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Abstract
Clinical and experimental studies demonstrate an interaction among bones, adipose 
tissue and diabetes mellitus: obese women have lower risk of fractures, whereas diabe-
tes and hypertension were associated with osteopenia and osteoporosis. Today, bone 
is considered not solely as a supporting and protective structure, but also an active 
endocrine organ producing secretory proteins collectively termed osteokines. in this 
presentation, the role of two of these factors, leptin and osteocalcin, as well as the tran-
scription factors FOX01 and ATF4, in the control of glucose and energy homeostasis is 
briefly highlighted. 
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Introduction
Metabolic diseases of glucose, lipid 
and of bone increase with advanc-
ing age. Diabetes mellitus is the pro-
totype for disorders of glucose me-
tabolism and osteoporosis of bone. 
Observational studies have shown 
that bone mineral density (BMD), a 
measure of bone mass, is altered in 
subjects with type 1 diabetes mellitus 
and metabolic syndrome. Recent stud-
ies have shown that in both men and 
women with type 2 diabetes mellitus, 
the prevalence of osteoporosis and of 
hip fracture is higher (1-3). However, 
the prevalence of osteoporosis was not 
increased in subjects with pre-diabe-
tes (4) or with metabolic syndrome 
(5). A number of factors have been 
implicated in the dichotomy between 
osteoporosis in prediabetes and diabe-
tes, namely that bone quality depends 
on aspects other than bone density 
alone, for example, bone architecture, 
turnover, accumulation of microdam-
age, mineralization and properties of 
bone matrix proteins (6). Advanced 
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glycation end products in the bone can predispose it to fracture 
by interacting with its receptors (6). Subjects with type 2 dia-
betes mellitus enjoy little benefit from elevated BMD, in terms 
of improved bone load to strength ratios (7). Other risk factors 
such as plasma lipids (8-10) and body weight were also related 
to bone disorders. Many reasons have been put forth to explain 
the altered BMD in diabetes mellitus including increased body 
mass index (BMI), hyperglycemia or insulin resistance (8-10). 
Similarly, drugs used in osteoporosis (bisphosphonates) and dy-
slipidemia (statins) were shown to inhibit atherosclerosis and to 
also alter BMD, respectively (11). In addition, common bone-as-
sociated proteins were shown to regulate atherosclerotic plaque 
formation (12). 
The interrelation between bone and glucose metabolism be-
gan to be unraveled with recent work on leptin and other bone-
derived secretory proteins (osteokines) (also see Manning’s re-
view on injured Homo obesus, in this volume of Adipobiology).
Metabolism-related osteokines
Leptin 
Leptin was first discovered as endocrine product of white adi-
pocytes, and later, in non-adipose tissues, including bone (13-
16). A combination of phenotypic, chemical and genetic studies 
suggested an integral function among leptin, bone metabolism 
and a central hypothalamic interaction via serotonin. Leptin 
deficient (ob/ob) and leptin receptor-deficient (db/db) mice 
were hypogonadal and had high bone mass (14). Similarly pa-
tients taking serotonin reuptake inhibitors over long periods, 
which increases serotonin concentrations, have been reported 
to exhibit low bone mass, increased appetite and weight gain. 
It was hypothesized that serotonin is an ancestral molecule that 
increases appetite; during evolution, when the skeletal system 
developed, serotonin took on the additional role of increasing 
bone formation (17). Leptin, which was first identified in verte-
brates, inhibits serotonin synthesis, and thereby bone mass and 
appetite (17). This may represent a link between bone remod-
eling and energy metabolism (18,19,20).
Osteocalcin 
In addition to directly acting on the brain, there could be a re-
ciprocal regulation of bone and energy metabolism by leptin and 
osteocalcin. Undercarboxylated osteocalcin (referred to as os-
teocalcin onward), a product of osteoblasts, is a hormone affect-
ing insulin production by the pancreas and insulin sensitivity in 
peripheral tissues, at least in part through enhanced secretion of 
adiponectin from adipocytes. Osteocalcin knockout knockout 
mice exhibiting obesity, hyperglycemia, and decreased insulin 
secretion relative to wild-type mice (21-27). Leptin inhibits in-
sulin secretion by pancreatic beta cells, while osteocalcin has the 
opposite effect. It acts via sympathetic innervation of osteoblasts 
whereby it upregulates sympathetic tone, enhances Esp expres-
sion in osteoblasts and decreases osteocalcin bioactivity. The 
functional relationship among adipocytes, sympathetic nervous 
system and osteoblasts reveals the important role skeleton can 
play in regulating glucose homeostasis.
The occurrence of insulin receptor in a variety of cells other 
than those of muscle, liver and kidney suggested insulin could 
have a broader role to play. In animal models developed with 
gain-of-function function for osteocalcin, there was increased 
pancreatic beta cell proliferation, as well as insulin expression 
and secretion. It enhanced energy expenditure and increased the 
adiponectin expression; the latter is a well recognized insulin-
sensitizing hormone secreted by the adipocytes. In vitro studies 
showed that beta cell proliferation and insulin expression are af-
fected by low concentrations of osteocalcin, ranging from 0.03 to 
0.3 ng/ml. In vivo, low concentrations of osteocalcin upregulated 
insulin secretion and beta cell proliferation. Continuous deliv-
ery of osteocalcin of osteocalcin in wild type mice improved glu-
cose load handling and decreased the mass of fat. These changes 
led to a decrease in obesity and type 2 diabetes mellitus. 
Thus, osteoblasts and osteoclasts could contribute to glucose 
homeostasis, with osteoblasts acting via the hormone osteocal-
cin and osteoclasts acting acting through insulin mechanisms 
(18). There is interplay between the two cell types, where insulin 
signaling in osteoblasts increases osteocalcin activity, which in 
turn increases bone resorption (19).
Together these studies suggest that the osteokines leptin and 
osteocalcin exert an endocrine control on glucose and energy 
homeostasis (21-27). 
Clinical observations
Data from a completed clinical trial involving adults aged 60 
years or older (n=380, mean age 71 years, BMI 26.9 kg/m2; 5% 
had diabetes mellitus) was re-evaluated to investigate the rela-
tionship between osteocalcin concentrations and markers of 
metabolic syndrome (22). Interestingly, the serum osteocalcin 
concentrations were inversely associated with hyperglycemia, 
insulin resistance, systemic inflammation and body mass index. 
Over time, changes in osteocalcin concentrations also predicted 
the occurrence of hyperglycemia (20). In another study involv-
ing a Japanese cohort (171 men, 149 postmenopausal women), 
serum osteocalcin concentrations were inversely associated 
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first demonstration in mammals that Fox01 to Fox01 signaling 
occurs between different tissues thereby resulting in Fox01 levels 
in bone regulating Fox01 activity in the pancreas or liver.
By coordinating the bone and pancreas through positive 
feedback regulation, there could be an alignment in the rate of 
metabolic activity between skeleton and the pancreas. In situa-
tions where the skeletal and glucose handling deteriorate such as 
in aging, Fox01 may “confer a rescuing signal of energy supply 
from the wasting skeleton to the energy demanding organs that 
control glucose metabolism“(28). 
See Editorial on page 73-75
ATF4 
ATF4 (activating transcription factor 4) accumulates predomi-
nantly in osteoblasts. It is involved in the maintenance of bone 
mass. Mice with Atf4-/- showed smaller fat pads than controls, it 
was suggested that ATF4 could have a role in energy metabolism 
(29). Along with other transcription factors, e.g., Runx2 and 
Ostorix, ATF4 is a member of cAMP-responsive element bind-
ing protein (CREB) family of basic zipper-containing proteins. 
ATF4 regulates functions of the osteoblast related to the control 
of bone mass. In a mouse model, inactivating ATF4 enhanced 
the secretion of and sensitivity to insulin. However it did not af-
fect insulin sensitivity in isolated liver cells, and could influence 
liver cells through another cell type. Overexpression of ATF4 in 
osteoblasts inhibited insulin secretion and reduced insulin sen-
sitivity. Thus another novel pathway between bone cells and en-
ergy metabolism was shown in knockout animal model. 
Other associations
Osteoprotegerin and diabetes
Osteoprotegerin (OPG) is a member of tumor necrosis factor 
receptor superfamily (30). It acts as a decoy receptor for receptor 
activator of nuclear factor-KB ligand (RANK1). Osteoprotegerin, 
which prevents osteoclast activation and bone resorption, is also 
found in many tissues including lung, heart and kidney. A re-
cent study showed that the level of OPG was increased in sub-
jects with diabetes. Elevated levels of OPG were predictive of 
all-cause mortality in type 2 diabetes mellitus independent of 
known conventional risk factors (30).
Vitamin D and energy metabolism
There is recent evidence that vitamin D affects energy metabo-
lism as well as biology of adipocytes through mechanisms in-
cluding the regulation of B-oxidation and expression of uncou-
with glucose and adiponectin levels, fat mass and parameters of 
atherosclerosis in subjects with type 2 diabetes mellitus (23). A 
negative correlation was associated with fasting plasma glucose 
and glycosylated hemoglobin in both sexes. Hyperglycemia sup-
pressed osteocalcin expression in osteoblasts. Thus serum osteo-
calcin secreted from osteoblasts could modulate pancreatic beta 
cell function and impact glucose metabolism (23). This suggests 
that strategies to regulate glucose metabolism can be designed 
by modulating the activity or production of bone-specific pro-
teins.
Metabolism-related transcription factors in bone 
Fox01 (Forkhead Box 01) expression in osteoblasts could play a 
role in regulating glucose metabolism through osteocalcin (28). 
Fox01 is a transcription factor that regulates glucose homeosta-
sis via modulation of insulin signaling in many tissues including 
adipocytes, pancreatic beta cells, hepatocytes and myoblasts. In 
the liver cells it promotes gluconeogenesis by acting in concert 
with PPAR gamma coactivator, stimulating expression of glu-
cose-6 phosphatase and phosphoenolpyruvate kinase. Fox01 
thereby controls glucose metabolism at the level of beta cell pro-
liferation and at hepatic glucose metabolism. Rached et al (28) 
evaluated the function of Fox01 in other tissues, where its role is 
not so well known. Osteoblast-derived osteocalcin is negatively 
regulated by osteoblast gene, Esp. Protein tyrosine phosphatase, 
a product of Esp decreases the bioactivity of osteocalcin protein 
by favouring its carboxylation. Fox01 acts through stimulation 
of osteocalcin and inhibition of Esp to influence glucose metab-
olism via the osteoblasts. As a result, of these complementary 
functions it acts through osteoblast modulation to negatively 
regulate energy metabolism. Mice model lacking Fox01 only in 
osteoblasts had increased beta cell proliferation, insulin secre-
tion and insulin sensitivity. Thus osteoblast specific Fox01 de-
ficiency could be responsible for increased expression of osteo-
calcin and reduced Esp expression, the latter a gene that encodes 
a protein, which decreases bioactivity of osteoclasts. It appeared 
that Fox01 in osteoblasts controlled glucose homeostasis by reg-
ulation of both expression and carboxylation of osteocalcin as 
an effector molecule. The postulated mechanism involved two 
processes in which Fox01 directly inhibits osteocalcin expres-
sion by binding to its promoter, and promoting carboxylation. 
In turn, uncarboxylated osteocalcin mediates metabolic ac-
tions of osteoblasts. It also suppresses osteocalcin bioactivity by 
stimulating the expression of Esp. In summary, Fox01 inhibited 
osteocalcin expression, increased its carboxylation and led to in-
sulin resistance, glucose intolerance and adiposity. This was the 
Adipobiology 2, 2010
Osteokines and energy homeostasis70 RevIew
pling proteins (31). Vitamin D receptor ligands can act through 
the immune system to modulate the occurrence of autoimmune 
diseases such as type 1 diabetes mellitus (32). A recent clinical 
study in Arab Americans men has shown that vitamin D defi-
ciency was associated with insulin resistance and glucose intol-
erance (33).
Conclusion
Studies from epidemiological, clinical, biochemical and knock-
out models have suggested an interaction between bone secre-
tory activity with lipid, glucose and energy metabolism. This 
could further be explored in the pathogenesis and therapy of 
cardiometabolic diseases.
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